KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Novavax (NVAX) Income from Continuing Operations (2016 - 2025)

Novavax has reported Income from Continuing Operations over the past 16 years, most recently at 17527000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 17527000.0 for Q4 2025, up 121.63% from a year ago — trailing twelve months through Dec 2025 was 440302000.0 (up 334.83% YoY), and the annual figure for FY2025 was 440302000.0, up 334.83%.
  • Income from Continuing Operations for Q4 2025 was 17527000.0 at Novavax, up from 202379000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for NVAX hit a ceiling of 518646000.0 in Q1 2025 and a floor of 846284000.0 in Q4 2021.
  • Median Income from Continuing Operations over the past 5 years was 158081500.0 (2022), compared with a mean of 134697450.0.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 1910.83% in 2021 and later surged 451.51% in 2025.
  • Novavax's Income from Continuing Operations stood at 846284000.0 in 2021, then soared by 78.46% to 182249000.0 in 2022, then grew by 2.12% to 178389000.0 in 2023, then surged by 54.58% to 81030000.0 in 2024, then surged by 121.63% to 17527000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 17527000.0 (Q4 2025), 202379000.0 (Q3 2025), and 106508000.0 (Q2 2025) per Business Quant data.